Compare ASTRAZENECA PHARMA with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALEMBIC - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALEMBIC ASTRAZENECA PHARMA/
ALEMBIC
 
P/E (TTM) x 134.3 57.8 232.2% View Chart
P/BV x 37.7 5.0 756.0% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   ALEMBIC
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALEMBIC
Mar-18
ASTRAZENECA PHARMA/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs1,27872 1,775.0%   
Low Rs88334 2,603.5%   
Sales per share (Unadj.) Rs228.44.7 4,859.0%  
Earnings per share (Unadj.) Rs10.46.1 169.8%  
Cash flow per share (Unadj.) Rs16.36.2 260.4%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.840.7 242.9%  
Shares outstanding (eoy) m25.00267.03 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.711.3 42.0%   
Avg P/E ratio x104.28.7 1,201.5%  
P/CF ratio (eoy) x66.48.5 783.6%  
Price / Book Value ratio x10.91.3 839.9%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m27,00814,139 191.0%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,535207 740.3%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,7101,255 454.9%  
Other income Rs m123370 33.1%   
Total revenues Rs m5,8331,625 358.8%   
Gross profit Rs m463111 416.7%  
Depreciation Rs m14738 389.9%   
Interest Rs m02 0.0%   
Profit before tax Rs m438442 99.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17924 747.0%   
Profit after tax Rs m2591,630 15.9%  
Gross profit margin %8.18.9 91.6%  
Effective tax rate %40.85.4 753.5%   
Net profit margin %4.5129.8 3.5%  
BALANCE SHEET DATA
Current assets Rs m3,2091,867 171.9%   
Current liabilities Rs m2,070591 350.1%   
Net working cap to sales %20.0101.6 19.6%  
Current ratio x1.63.2 49.1%  
Inventory Days Days7294 76.7%  
Debtors Days Days3574 47.5%  
Net fixed assets Rs m7901,791 44.1%   
Share capital Rs m50534 9.4%   
"Free" reserves Rs m2,41910,324 23.4%   
Net worth Rs m2,46910,858 22.7%   
Long term debt Rs m041 0.0%   
Total assets Rs m4,60511,591 39.7%  
Interest coverage xNM260.9-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.1 1,144.9%   
Return on assets %5.614.1 40.0%  
Return on equity %10.515.0 69.9%  
Return on capital %17.715.2 116.8%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m30019 1,544.1%   
Fx outflow Rs m2,015264 763.7%   
Net fx Rs m-1,715-244 701.8%   
CASH FLOW
From Operations Rs m88236 37.3%  
From Investments Rs m-94-224 41.8%  
From Financial Activity Rs mNA-27 0.0%  
Net Cashflow Rs m-6-15 38.5%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 150.0%  
FIIs % 15.7 9.7 161.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.1 34.9%  
Shareholders   12,856 54,701 23.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  GSK PHARMA  VENUS REMEDIES  DR. REDDYS LAB  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS